CLAIMS:

1. Peptide having 13-55 amino acid residues characterized in that said peptide comprizes the amino acid sequence

A G W L R_1 D R_2 R_3 R_4 R_5 Y P I

in which R_1 = A, S
R_2 = Q, R, G
R_3 = T, S
R_4 = V, L
R_5 = R, Q.

with the provision that the peptide is not SSAGWLADRSVRYPISKARPNXGG, NAGWLSDGSVQYPITKPREP, DAGWLADGHSVRYPISRPRKR, GGLDWCNAGWLSDGSVQYPITKPR or EQLFAAYEDGFEQCDAGWLADQTVRYPIRAPRVGCY.

2. Peptide having 13-55 amino acid residues characterized in that said peptide comprizes at least the amino acid sequence

A G W L R_1 D R_2 R_3 L R_5 Y P I

in which R_1 = A, S
R_2 = Q, R, G
R_3 = T, S
R_5 = R, Q.

3. Peptide having 13-55 amino acid residues characterized in that said peptide comprizes at least one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.

4. Peptide consisting of one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.

5. Peptide having 13-55 amino acid residues and comprizing the amino acid sequence A G W L R_1 D R_2 R_3 R_4 R_5 Y P I in which R_1= A, S, R_2 = Q, R, G, R_3 = T, S, R_4 = V, L, and R_5 = R, Q, for use as a medicament.

6. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R_1 D R_2 R_3 R_4 R_5 Y P I in which R_1= A, S, R_2 = Q, R, G, R_3 = T, S, R_4 = V, L, and R_5 = R, Q, and a pharmaceutical acceptable carrier.

7. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R_1 D R_2 R_3 L R_5 Y P I in which R_1= A, S, R_2 = Q, R, G, R_3 = T, S and R_5 = R, Q, and a pharmaceutical acceptable carrier.

8. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing at least one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.

9. Pharmaceutical preparation comprizing at least one of the peptides· AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLADGSLRYPI and AGWLSDGSVQYPI and a pharmaceutical acceptable carrier.

10. Use of a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R_1 D R_2 R_3 R_4 R_5 Y P I in which R_1= A, S, R_2 = Q, R, G, R_3 = T, S, R_4 = V, L, and R_5 = R, Q, for the manufacture of a pharmaceutical preparation for use in a peptide-induced tolerance therapy for the induction of tolarance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases.